Purpura, easy bruising, mucocutaneous bleeding (adult, child)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Purpura with fever: purpura fulminans, absolute emergency
- No tests before treatment: call the emergency medical service (SAMU-Centre 15).
- Ceftriaxone without delay, preferably intravenous, otherwise intramuscular: 1 to 2 g in adults; 50 to 100 mg/kg not exceeding 1 g in children (cefotaxime if ceftriaxone is not available).
- Blood culture or blood sample only if it does not delay the antibiotic.
Purpura without fever (petechiae, spontaneous bruising): FBC the same day
Laboratory tests the same day
- FBC with platelets and blood film examination
- Serum creatinine with eGFR
Urine tests
- Urine dipstick (proteinuria, haematuria)
- Urine protein:creatinine ratio (spot sample) (if dipstick positive for protein)if needednon-French guidelineVascular purpura (normal platelets) with proteinuria on dipstick: quantification guides management (renal biopsy, nephrology advice) in IgA vasculitis [6].
Also consider
Easy bruising or mucocutaneous bleeding with normal platelets: bleeding disorder?
- First a standardised bleeding questionnaire (personal and family): tests are useful only if it suggests a haemostasis disorder.
Laboratory tests (citrate tube, away from a bleed, an infection or a pregnancy)
- FBC with platelets
- PT, aPTT
- Fibrinogen
- Screen for von Willebrand disease: von Willebrand factor activity and factor VIII (the laboratory scientist adds the antigen if needed)
- CRP (if inflammation is possible, to interpret von Willebrand factor)if neededPossible inflammatory context: an inflammatory syndrome raises von Willebrand factor and can mask von Willebrand disease [1].
- ASTif needednon-French guidelinePossible liver disease: the German recommendation (DGHO, 2025) and the Scottish NHS Lothian guide look for an acquired cause with liver function tests, the liver synthesising the clotting factors [9,10]. The French PNDS on von Willebrand disease does not address this point [1].
- ALTif needednon-French guidelinePossible liver disease: the German recommendation (DGHO, 2025) and the Scottish NHS Lothian guide look for an acquired cause with liver function tests, the liver synthesising the clotting factors [9,10]. The French PNDS on von Willebrand disease does not address this point [1].
- Serum creatinine with eGFR (if renal failure is possible)if needednon-French guidelinePossible renal failure: the German recommendation (DGHO, 2025) and the Scottish NHS Lothian guide also look for this acquired cause, uraemia impairing platelet adhesion and aggregation [9,10]. The French PNDS on von Willebrand disease does not address this point [1].
- TSH (if signs of hypothyroidism)if needednon-French guidelineSigns of hypothyroidism: the German recommendation (DGHO, 2025) and the Scottish NHS Lothian guide cite the thyroid, hypothyroidism being associated with impaired platelet function and a prolonged bleeding time [9,10]. The French PNDS on von Willebrand disease does not address this point [1].
- Serum ferritin (if heavy periods, repeated bleeding or microcytic anaemia)if needednon-French guidelineRepeated bleeding: the German recommendation (DGHO, 2025) has iron assessed, a hypochromic microcytic anaemia reflecting repeated losses, especially with heavy periods [9]. The French PNDS deals with associated iron deficiency, without including it in the initial work-up [1].
- Serum protein electrophoresis (if bruising or bleeding starting after 40 years without a cause found)if needednon-French guidelineAcquired disorder after age 40: the Scottish NHS Lothian guide then asks for electrophoresis, and the German recommendation (DGHO, 2025) cites it among the possible tests, a monoclonal gammopathy being able to cause acquired von Willebrand disease [9,10]. The HAS (French National Authority for Health) does not cite bruising among its indications for first-line prescription [11].
- State the ABO blood group on the prescription if known (blood group card).
- ABO blood group (only if not known, to interpret von Willebrand factor)if neededPatient’s blood group unknown: von Willebrand factor is interpreted according to ABO group, its levels being 25 to 35% lower in group O subjects [12,13]. Do not request it routinely: the diagnostic thresholds (< 30%, or < 50% in a patient who bleeds) apply whatever the group [14].
- State on the prescription any anticoagulant, antiplatelet or NSAID.
Also consider
- Heavy periods? See the page “Heavy menstrual bleeding”.
- Prolonged aPTT? An isolated prolonged aPTT falls under the page “Isolated prolonged aPTT”.
Do not order
- “Routine” haemostasis tests, notably before a procedure, with no suggestive history or clinical finding: not recommended [15].
- Bleeding time: its limitations and poor value are established [15]; it is no longer listed in the French laboratory fee schedule (NABM) [16].
- ABO blood group requested routinely to interpret von Willebrand factor: the diagnostic thresholds apply whatever the group [14]; record it if known, request it (not reimbursed) only if unknown [13,16].
Sources (18)
- Centre de référence de la maladie de Willebrand (CRMW), filière MHémo. Protocole national de diagnostic et de soins (PNDS) : Maladie de Willebrand, février 2021, et synthèse à destination du médecin traitant (publiés sur has-sante.fr ; non validés par la HAS).
- Agence régionale de santé de Corse. Aide-mémoire sur les infections invasives à méningocoque (IIM), juin 2022 (synthèse de l'instruction n° DGS/SP/2018/163 du 27 juillet 2018 relative à la prophylaxie des IIM).
- ANSM. Résumé des caractéristiques du produit CEFTRIAXONE EG 1 g/10 ml, poudre et solvant pour solution injectable, rubriques 4.1 et 4.2 (mise à jour du 26/07/2013).
- National Institute for Health and Care Excellence (NICE). Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management. Guideline NG240, mars 2024. Recommandations 1.1.9 et 1.2.5.
- Robert Koch-Institut (Allemagne). RKI-Ratgeber : Meningokokken, invasive Erkrankungen. État au 5 février 2026.
- Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):S1-S71.
- National Institute for Health and Care Excellence (NICE). Suspected cancer: recognition and referral. Guideline NG12, juin 2015, mise à jour 15 avril 2026. Recommandations 1.10.1 et 1.10.2 (leucémies) et définition de « very urgent ».
- Manchester University NHS Foundation Trust (MFT). Haematology GP Pathway Guides, version 4, mars 2026 : parcours « Easy Bruising ».
- Gebhart J, Casini A, Knöfler R, Streif W, Zieger B, Trautmann-Grill K, Alesci RS, Kirschner M. Abklärung einer Blutungsneigung. Onkopedia, recommandation de la DGHO (société allemande d'hématologie et d'oncologie, avec les sociétés autrichienne et suisse), état août 2025.
- NHS Lothian. RefHelp : Unexplained bleeding (haematology referral guideline), version de juillet 2023, page modifiée le 11 mars 2025.
- Haute Autorité de santé. Fiche mémo : Quand prescrire une électrophorèse des protéines sériques (EPS) et conduite à tenir en cas d'une immunoglobuline monoclonale. Janvier 2017 (version mise à jour avec la mention de novembre 2025 sur la VS).
- Centre de référence de la maladie de Willebrand (CRMW). PNDS Maladie de Willebrand : argumentaire scientifique, février 2021.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 0192 (dosage fonctionnel du facteur Willebrand).
- James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280-300.
- Molliex S, Pierre S, Bléry C, Marret E, Beloeil H. Examens préinterventionnels systématiques. Recommandations formalisées d'experts de la Société française d'anesthésie et de réanimation. Ann Fr Anesth Reanim. 2012;31(9):752-63.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 1140 (phénotypage érythrocytaire ABO RH1/D) ; absence d'acte pour le temps de saignement.
- Haute Autorité de santé. Maltraitance chez l'enfant : repérage et conduite à tenir. Fiche mémo, octobre 2014, mise à jour juillet 2017.
- Hughes PR, Lewis MN, Adams SS. Bleeding and Bruising: Primary Care Evaluation. Am Fam Physician. 2024;110(5):504-514.